Drugs / FLU-v
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03180801 | Aug 2016 → Mar 2017 | influenza | PepTcell Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLU-v | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03180801 ↗ |
| Modality | Peptide | “novel peptide vaccine” NCT03180801 ↗ |
| Route | Subcutaneous | “Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51” NCT03180801 ↗ |